Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2705 participants.

Also called NCT01289990

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,705 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01289990
  • EudraCT 2010-022718-17
Other papers using this trial's data
  • Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes Diabetes research and clinical practice, 2015-10 DOI, PubMed 26324220
  • Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial Cardiovascular diabetology, 2015-12-23 DOI, PubMed 26701110, PMC4690334 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, China, France, Germany, Greece, India, Ireland, Japan, Mexico, Philippines, Slovakia, Slovenia, South Korea, Switzerland, Taiwan, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01289990. Non-randomized; double masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-07-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Sitagliptin 100mg
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01289990
Content hash
589403619b97328d36ae41a4474712d4529bfe59c87feb9f74354bdcdaa91946